Palvella Therapeutics (NASDAQ:PVLA) Given Buy Rating at BTIG Research

BTIG Research reissued their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note released on Thursday,Benzinga reports. The brokerage currently has a $192.00 price objective on the stock.

PVLA has been the subject of several other reports. Truist Financial boosted their price objective on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a report on Monday, December 15th. Mizuho began coverage on shares of Palvella Therapeutics in a research report on Wednesday, January 7th. They set an “outperform” rating and a $205.00 price target for the company. UBS Group reissued a “buy” rating and set a $143.00 price target on shares of Palvella Therapeutics in a research note on Monday, December 15th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. Finally, Oppenheimer reiterated an “outperform” rating and set a $200.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $158.69.

Palvella Therapeutics Stock Performance

NASDAQ:PVLA opened at $81.90 on Thursday. The company has a market cap of $969.70 million, a price-to-earnings ratio of -31.14 and a beta of -0.16. The stock’s fifty day moving average price is $96.94 and its two-hundred day moving average price is $71.96. Palvella Therapeutics has a 52-week low of $12.60 and a 52-week high of $114.69.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Monday, November 10th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18). On average, equities analysts predict that Palvella Therapeutics will post -3.69 EPS for the current fiscal year.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders sold 12,906 shares of company stock worth $1,205,980. Company insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently modified their holdings of the business. First Light Asset Management LLC acquired a new position in shares of Palvella Therapeutics in the 3rd quarter valued at approximately $33,949,000. Federated Hermes Inc. bought a new position in Palvella Therapeutics in the third quarter valued at approximately $21,255,000. Vanguard Group Inc. lifted its stake in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after buying an additional 330,847 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Palvella Therapeutics in the first quarter valued at approximately $7,553,000. Finally, Fred Alger Management LLC increased its position in shares of Palvella Therapeutics by 1,279.1% during the third quarter. Fred Alger Management LLC now owns 186,751 shares of the company’s stock worth $11,707,000 after acquiring an additional 173,209 shares in the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.